MIRNAX BIOSENS is a biotech company that develops new technologies, based on liquid biopsy, for the fast and direct diagnosis and prognosis of pathologies without a effectice current method.
MIRNAX has developed an innovative technological platform that allows the detection of genetic markers from non-invasive biological samples such as blood, urine or saliva (liquid biopsy).This platform, MiRNAX platform, is based on RT-qPCR technology and it provides an integral solution that covers all phases of the process:
- Sample preparation: nucleic acid extraction and preservation technology included
- Amplificationn: suitable amplification of genetic markers, such as DNA, RNA, miRNAs, lnRNAs, etc. (PCR).
- Detection: quantification of genetic markers in real time (qPCR).
In terms of exploitation of the MiRNAX platform, the company has developed different diagnostic and/or prognostic kits for the detection of diseases and clinical conditions whose diagnosis through the identification of miRNA type biomarkers is possible and it is implanted or in the process of implantation within the medical-scientific community.
The first kit that the company will launch is a test for the early diagnosis of acute kidney injury, a disease that currently lacks an effective method for diagnosis and that negatively compromises the patients' lives.
Mirnax Biosens is starting the semi-clinical validation of this first kit.